~//bj.watch/overview
live

concept dossier

Blueprint Protocol

The Blueprint Protocol is bryan johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs and biomarkers should have more authority than cravings or cultural defaults.

protocollongevityhealthbiomarkersbiohackingautomation

// Habits · Longterm · Don’ts

Blueprint Protocol: habits, longterm, and don’ts

Three buckets keep practical routines, long-range interpretation, and source-aware caution visible on every protocol surface.

repeatable behaviors

Habits

  • Run the measurement loop: bloodwork, wearables, oral/skin/organ metrics, then retest instead of relying on vibes.concepts/blueprint-protocol.md
  • Keep the stable inputs visible first: consistent sleep, training, nutrient-dense meals, oral care, light exposure, and recovery.concepts/blueprint-protocol.md
durable strategy

Longterm

  • Treat Johnson’s October 2026 young-stroke relay as an attributed research relay with an exactly verified core figure and aged-up framing. “Strokes in young people used to be considered freak events… In stroke patients aged 18–35, those with 3+ major cardiovascular warning signs jumped by 50% in eight years. The culprits: high blood pressure, high cholesterol, obesity, and smoking.” traces to “Temporal Trends in Vascular Risk Factor Burden Among Young Adults With Ischemic Stroke — The Florida Stroke Registry,” Neurology, March 25, 2025 (10.1212/WNL.0000000000213447): 36,488 GWTG-Stroke ischemic-stroke patients 2014–2022, 3,363 aged 18–35, 3+ VRF polymorbidity 10.9%→16.4% (p=0.002) — a 50.4% relative jump in exactly eight years, with the post’s four named culprits all on the paper’s nine-factor list. Boundaries: hospitalized-patient share, not population risk; relative not absolute (5.5 percentage points); Florida hospital registry, not a population sample; “new study” is 19 months old and unnamed; “bodies of 60 yr olds” is gloss — risk-factor counts, not biological age; association, not demonstrated cause. Not evidence about any reader’s stroke risk, a screening recommendation, or medical advice.https://x.com/bryan_johnson/status/2115912558372626513
  • Treat Blueprint as a repeatable feedback system whose rules can evolve as biomarkers, symptoms, or evidence change.concepts/blueprint-protocol.md
  • Track the June 2026 sauna/HSP27 thread as a protocol-design case study: Johnson shifted the dose question from minutes in the sauna to measured core temperature and biomarker response.raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md
  • Treat the July 2026 sauna checklist as Johnson’s attributed protocol guidance. Its 4–7-session frequency, heat-dose targets, fertility and microplastics claims, hydration advice, and environmental cautions are not a reader prescription or independent evidence of longevity benefit.raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md
  • Track the June 2026 jet-lag follow-up as a self-reported caffeine + melatonin test using blood glucose as a body-clock readout, not as general travel medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-19.md
  • Treat the June 2026 Australian sun/skin-aging post as a skin-readout example inside the measurement loop, not as validated skincare advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md
  • Treat the June 2026 Immortals Rx expansion separately from foundational habits; the GLP-1, SGLT2, peptide, and NAD+ catalog is a commercial/protocol claim that requires clinician oversight.raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md
  • Treat the July 2026 six-option GLP-1 catalog as an Immortals Rx commercial update. Johnson names branded and compounded listings, but the post does not establish formulation status, availability, prescribing criteria, or safety and efficacy for longevity use.raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md
  • Treat Johnson’s August 2026 Viagra-plus-statins cancer-spread post as a low-confidence intervention claim. He identifies the cited work as preclinical and the human evidence as observational; his proposed extension from sildenafil to tadalafil is not evidence of efficacy or a reason to combine medicines.raw/articles/bryan-johnson/x-twitter-daily-2026-08-04.md
  • Treat Johnson’s June 2026 “one international trip per quarter” rule as a biomarker-derived personal boundary, not as a reader travel guideline.raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md
  • Treat the June 2026 inherited-cancer DNA + RNA panel as germline risk-stratification context, not a diagnosis, universal screening recommendation, or validation of Johnson’s early-surveillance statistics.raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md
  • Treat the July 2026 AIG single-cell immune-receptor sequencing thread as Johnson’s diagnostic follow-through: a cellular/receptor-level measurement layer, not a validated therapy or reader test recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md
  • Treat the July 2026 low-ferritin / Monoferric follow-up as Johnson’s self-reported AIG case and false-negative philosophy, not a general iron-infusion recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md
  • Treat the July 2026 AIG cure roadmap and “Bryan in a dish” model as a proposed personal experiment; it is not an approved autoimmune-disease cure, validated ex-vivo screening protocol, or reader treatment pathway.raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md
  • Treat the July 2026 Kate Tolo endometriosis workup as multi-modality diagnostic-triangulation context; it is not a reader diagnostic pathway, independent validation, or proof that endometriosis can now be cured.raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md
  • Treat the October 2026 endometriosis organoid posts as an attributed method disclosure, not cure or therapy evidence. The stated approach — 30 mL of menstrual blood to build an organoid plus 30 mL for single-cell molecular characterization, to “model out her disease and can test potential therapies” — matches real published science: Turco et al. 2021 (Communications Biology, 10.1038/s42003-021-02194-y) derived endometrial organoids from menstrual flow with 87% success and transcriptomic identity to biopsy organoids, and Boretto et al. 2019 (Nature Cell Biology, 10.1038/s41556-019-0360-z) established patient-derived endometriosis organoids amenable to drug screening. But published menstrual-flow organoids model the eutopic endometrium, not surgically proven lesions; no lab, partner, cell line, characterization, therapy test, or outcome is published; and the volumes are self-reported. Not a collection protocol readers can follow or medical advice.https://x.com/bryan_johnson/status/2111861961394962672
  • Read Johnson’s October 2026 longevity-home energy ledger — 52 kWh/day for the longevity stack and 93 kWh/day for the whole house, against an EIA average-US-household ~29 kWh/day — as an attributed infrastructure disclosure, not a health claim or efficiency standard. The arithmetic is internally consistent (device list sums to 52 kWh; 52 × 80 ≈ the posted 4,200 phone charges), but the figures are self-reported single-day readings, the solar self-consumption (64 − 33 = 31 kWh) does not cover the longevity demand, the “80 phone charges per kWh” rendering assumes a ~12.5 Wh battery, and the post implies nothing about whether any listed device affects longevity outcomes.https://x.com/bryan_johnson/status/2112320547828945248
  • Treat the October 2026 rapamycin-retrospective post as an attributed N=1 deprescribing narrative with real literature behind it, not a drug decision readers can transfer. Johnson stopped rapamycin September 28, 2024 (per his own Blueprint essay) after ~5 years of weekly/biweekly/alternating dosing produced what he calls a “mixed story” — skin/soft-tissue infections, lipid abnormalities, glucose elevations, higher resting heart rate — and the peer-reviewed skepticism he now cites verifies in direction (Lancet Healthy Longevity systematic review: immune/cardiovascular/integumentary gains but no endocrine/muscular/neurological effects and adverse lipid/infection signals; Frontiers in Aging 2025 and Aging 2024 reviews citing unresolved human efficacy). None of this tells any other person to stop or start rapamycin; it is monitoring-grade evidence about uncertainty.https://x.com/bryan_johnson/status/2112642762353021020
  • Read the October 2026 minoxidil Phase 3 comparison as competitive pharmacy marketing built on accurately quoted but non-comparable numbers. His 36.4 hairs/cm² (Veradermics VDPHL01 17 mg/day, n=536 placebo-controlled Phase 3) vs 35.9 hairs/cm² (Panchaprateep & Luengarun, 5 mg/day, n=30 open-label) juxtaposition is cross-trial, not head-to-head — different populations, doses, formulations, and measurement methods — and the post pivots the comparison into “available now at my Immortals Pharmacy,” while low-dose oral minoxidil is off-label prescribing territory requiring clinician oversight. Not evidence of drug equivalence or a hair-loss treatment recommendation.https://x.com/bryan_johnson/status/2112558564216868987
  • Read Johnson’s October 2026 gray-market peptide warning as a verified consumer-safety relay, not a purchasing directive. Every checkable figure in the post matches the public record — TRM Labs’ October 6 blockchain analysis (150+ Chinese chemical vendors taking crypto, ~75% listing both peptides and fentanyl precursors, inflows $28.2M→$37.3M over 2023–2025, ~57% of identifiable value US-sourced), the WSJ’s ~200-tracked-firms/at-least-50-selling-peptides count, Anhui Rencheng’s June 2023 DOJ indictment with semaglutide and Melanotan II still listed as of September 2026, CBP’s master-carton seizures (~400 operations, 2,400+ seizures, 130,000+ vials October 2025–August 2026), and the two FAERS retatrutide death reports CBS reported October 13 — but TRM cannot separate peptide revenue from precursor revenue, the deaths are unverified-causation adverse-event reports, retatrutide is an unapproved investigational drug, and Johnson’s own Immortals Pharmacy sells peptides as the regulated alternative, an adjacency the post leaves implicit. Not an indictment of all peptide use, evidence regulated alternatives are risk-free, or medical advice.https://x.com/bryan_johnson/status/2113024548643996051
  • Treat Johnson’s October 2026 N=1 self-critique as an attributed epistemic-boundary statement, not a repudiation of measurement. Endorsing an unnamed paper’s argument that his “biomarker numbers say less than people think” — aging is multi-scale and not directly measurable, “biomarkers are like the blind men touching the elephant,” N=1 shows “responsiveness but not durability; optimisation but not causality” — the position echoes the field’s own frameworks (no aging biomarker yet satisfies surrogate-endpoint validation; the TranslAGE database tests responsiveness, not outcome change). But the paper is unnamed and unlinked, the quoted critique is his transcription, and the proposed “simulation of aging system dynamics” is stated intent with no model, publication, or team disclosed. Not evidence biomarker tracking is useless, a disclosed research program, or medical advice.https://x.com/bryan_johnson/status/2112735624684093647
  • Read the October 2026 GLP-1 gut self-experiment announcement as intent without a protocol. “T cells trigger severe gut lining damage / GLP agonists directly protect against intestinal destruction / I’m going to test this on myself” rests on real mouse science — Koehler et al., Cell Reports Medicine (10.1016/j.xcrm.2026.103115): T-cell activation induces intestinal GLP-1/GLP-2 secretion, Glp1r/Glp2r-knockout and gut-proglucagon-deficient mice suffer worse αCD3-induced enteropathy, and semaglutide and teduglutide each attenuate the damage — but it is acute work in young male mice with an antibody-induced injury model that a healthy human cannot reproduce, and the post names no drug, dose, design, or outcome. Not a sanctioned self-experiment, gut-health guidance, or medical advice.https://x.com/bryan_johnson/status/2112970692157395083
  • Treat the October 2026 sauna equipment-and-rationale disclosure as attributed N=1 practice with a self-labeled hypothesis. The post itemizes “medical grade silicon,” ice on face, neck, scrotum, and CGM, 200°F (93°C), 20 min, 5×/week, and frames cooling face/neck as “a hypothesis of protecting from heat induced collagen breakdown” — his own hypothesis label, with directional cosmetic literature on heat and collagen but no test of the ice protocol itself; the silicon and ice-on-CGM details are personal practice, not a reader protocol.https://x.com/bryan_johnson/status/2112953793956737170
  • Read Johnson’s October 2026 “Take earplugs everywhere” post as an attributed prevention directive, not a reader audiology recommendation. The medical direction verifies — hearing impairment is independently associated with accelerated whole-brain and right-temporal atrophy (Lin et al., NeuroImage 2014, BLSA n=126, 6.4-year follow-up: 8.4 vs 7.2 cm³/year), and the 2024 Lancet Commission ranks hearing loss among its 14 modifiable dementia risk factors (HR 1.37; hearing aids associated with 17% lower dementia risk; ACHIEVE RCT protective effect confined to its high-risk subgroup) — but the “environments routinely above 85 dBA” venue list overstates the measured record for restaurants and coffee shops (NYC SoundPrint survey of 2,376 venues averages 77–78 dBA, 25% above 81; subway platforms average 80.4 dBA with ~20% over 85), 85 dBA is an 8-hour workplace time-weighted limit rather than a momentary danger line, the post names no study, and no trial shows earplugs prevent cognitive decline. Prevention framing with verified context, not a hearing-protection prescription or medical advice.https://x.com/bryan_johnson/status/2113385315801199010
  • Treat the October 2026 twice-yearly MRI readout as an attributed measurement disclosure, not evidence of youthful equivalence or a reader imaging recommendation. The self-reported figures — “subcutaneous and visceral fat - 20s equivalent,” “heart 100% score - 20s equivalent,” “hippocampal occupancy - 99th percentile,” scanner named as Prenuvo — summarize an unpublished private report with no reference cohort, normative dataset, or scoring method, and “radiologist report: my body is indistinguishable from an elite athlete” upgrades a quoted impression to a document. The screening-policy context the post omits: the American College of Radiology does not recommend total-body MRI screening for patients without symptoms, risk factors, or family history (April 17, 2023 statement), and the largest systematic review (J Magn Reson Imaging 2019, 10.1002/jmri.26736; 12 studies, 5,373 asymptomatic adults) found 32.1% pooled critical-or-indeterminate incidental findings with a 16.0% pooled false-positive proportion and no long-term verification of negative scans. Not evidence that twice-yearly whole-body MRI improves outcomes, a validated age-equivalence score, or medical advice.https://x.com/bryan_johnson/status/2115200763668631982
  • Read Johnson’s July 2026 “removing harm” list as a subtraction-first behavior philosophy. Sleep consistency, movement, avoiding nicotine/alcohol, and reducing obvious hazards belong with foundations; the post does not quantify each item or resolve the safety and attribution questions around his intervention stack.raw/articles/bryan-johnson/x-twitter-daily-2026-07-11.md
  • Treat the July 2026 Kate Tolo 90-day / 1,900-biomarker announcement as a projected N=1 program specification, not completed female-health evidence, a representative protocol, or medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
  • Treat Johnson’s RHR “Sovereignty Index” as within-person behavior-design framing. His reported 41 bpm average is not a universal target, and resting heart rate needs individual and clinical context.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
  • Treat the July 2026 ocular tear-panel post as an organ-specific measurement plan. Johnson reports a $1,800 specialty-lab panel across 15 biomarkers, but publishes no result, diagnosis, clinical utility, intervention, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md
  • Treat Immortals’ July 2026 disease-resolution infrastructure expansion as Johnson’s strategy and product positioning. The iPSC, organoid, deep-cell-characterization, and personalized-therapy directions do not establish an operational clinical platform, diagnosis, treatment, cure, safety, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md
  • Treat Johnson’s October 2026 female nighttime-erection measurement announcement as an attributed N=1 program-extension claim. The male physiology direction is real (Princeton III/IV consensus: ED onset precedes coronary events by 2–5 years), and female REM-linked genital engorgement is documented (Karacan et al. 1970; Fisher et al. 1983, Archives of Sexual Behavior, 10.1007/BF01541556 — cyclic engorgement in 95% of REM periods in 10 women), but the female evidence base is two small studies of vaginal blood flow with no outcome linkage, the device prices ($275 consumer vs. $15,723.68 lab) and 1,900-biomarker figures are program claims, and no published study validates female at-home erection scoring as a health-risk tool—not a monitoring recommendation for readers.https://x.com/bryan_johnson/status/2108705788986634435
  • Treat the July 2026 operational Kate Tolo baseline as an N=1 measurement program. The 100-day, 14-million-data-point plan with 100+ daily tasks, 50+ devices, and a 12-person team is not completed evidence, a representative female-health protocol, or reader guidance.raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md
  • Treat Johnson’s August 2026 claim that Kate Tolo’s protocol was built in 90 days and is “better” than his five-year build as an operational comparison only. No quality criteria, comparative measurements, outcomes, or external validation were published.raw/articles/bryan-johnson/x-twitter-daily-2026-08-05.md
  • Treat Johnson’s August 2026 47-tube, 250 mL blood draw as a scale and methods update. The post names single-cell immune sequencing and broad measurement domains but publishes no assay list, results, diagnosis, clinical interpretation, or evidence that collection volume improves outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-08-13.md
  • Treat Johnson’s August 2026 interval-training post as an attributed exercise claim, not a prescription. The 4×4 shape (3 sessions/week, 4 minutes at 90–95% effort with 3 easy minutes, 8 weeks) is the Helgerud et al. 2007 protocol (+7.2% VO2max), and the “11% lower all-cause mortality” figure compresses per-MET fitness associations (Kodama et al. 2009: 13% lower all-cause mortality per MET, RR 0.87)—no trial has measured mortality from eight weeks of intervals, and the post names no study.https://x.com/bryan_johnson/status/2092230490581574033
  • Treat Johnson’s August 2026 LDL post as an attributed cholesterol claim. The “49 trials, 312,175 people, ~23% fewer major vascular events per 39 mg/dL” figure matches Sabatine et al. 2016 (JAMA; RR 0.77 per 1 mmol/L), and the “13–14% over six months” diet figure matches the Jenkins et al. 2011 portfolio-diet RCT (−13.1% to −13.8% LDL from viscous fiber, nuts, plant protein, and plant sterols)—but the post names neither study, and trial-population relative effects are not individual guarantees or a lab-interpretation directive.https://x.com/bryan_johnson/status/2092597711543632216
  • Treat Johnson’s August 2026 NTE-by-age decline tables as an attributed normative-data claim. The age-related decline is documented (Karacan et al. 1975 normative NPT series; Schiavi et al. 1988; Horita & Kumamoto 1989: 189.6 min at age 20 declining to ~62 min at 70, nearly matching his age-20 anchor), but the post names no study, its intermediate bins match no single published cohort, and the repeated “2x risk in 4 years” outruns meta-analytic averages—not a validated risk prediction or monitoring recommendation.https://x.com/bryan_johnson/status/2093698799172829255
  • Treat Johnson’s September 2026 GLP-1 employment post as an attributed research relay. The underlying study is real (NBER w35387, Diamond: employment among baseline non-employed women rose 13.2 points overall and 26.9 points after six-plus quarters in the Understanding America Study), but Johnson’s “20–25 percentage point increase … over 2 to 3 yrs” paraphrase loosely brackets the paper’s horizons and stretches the window, and the post names no paper—not individual-outcome evidence or a reason to seek medication.https://x.com/bryan_johnson/status/2100763486850805808
  • Treat Johnson’s September 2026 son’s-sperm post as an attributed family measurement and advice list. The population anchor is documented (Levine et al. 2017: sperm concentration among unselected Western men fell 52.4% from 1973–2011), but the “top 1%” and “19x WHO minimum” rankings disclose no reference cohort, and the lifestyle list and parent-testing advice are generic guidance without individualization—not fertility guidance or medical advice.https://x.com/bryan_johnson/status/2098185202585747947
  • Treat Johnson’s August 2026 Kernel brain-scan percentile post as an attributed self-report. The regional percentiles (amygdala 95th, putamen 99th, caudate 97th, frontal gray matter 78th “and climbing”), heritability figures, and personality mappings are his own account against an undisclosed normative cohort; the plasticity literature he gestures at (Draganski et al. 2004: transient visual-motion-cortex gray-matter change from juggling; Colcombe et al. 2006: frontal-volume gains from aerobic exercise in older adults) does not validate region-by-region self-interpretation—not a brain-health metric, evidence the protocol grew his frontal cortex, or medical advice.https://x.com/bryan_johnson/status/2094112145357291863
  • Treat Johnson’s August 2026 nighttime-erection post as an attributed N=1 biomarker claim. ED does precede and predict cardiovascular events (Vlachopoulos et al. 2011 JACC meta-analysis: RR 1.48 CVD, 1.35 stroke; Krimpen cohort: HR 2.6 only for severely reduced rigidity), but his flat “2x risk in 4 years” outruns the meta-analytic averages, the post names no study, consumer NTE scores are not a validated clinical risk tool, and daily tadalafil 5 mg is a prescription medication requiring clinician oversight—not a reader protocol.https://x.com/bryan_johnson/status/2093061998468903267
  • Treat the Baseten biological-age event as public measurement positioning. Its brain, skin, strength, balance, reaction-speed, and mobility domains are not evidence that the tests form a validated or actionable biological-age score.raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md
  • Treat the August 2026 meibomian-gland post as an attributed N=1 diagnosis-and-intervention account. Johnson reports advanced MGD with gland dropout, a four-therapy stack (IPL, radiofrequency, intraductal probing, 630nm red light), and a self-reported 30% gland-function improvement; his own post says the probing science is unsettled and the therapies cannot be separated. It is not a validated eye-care protocol or reader guidance.https://x.com/bryan_johnson/status/2089822905891000605
  • Preserve medical-caution framing: this page summarizes Johnson/Blueprint practice, not personal treatment advice.concepts/biomarker-driven-longevity-protocols.md
guardrails

Don’ts

  • Do not present N=1 biomarker movement as proof of clinical outcomes.concepts/biomarker-driven-longevity-protocols.md
  • Do not mix experimental drugs, hormones, or supplements into the same confidence tier as sleep, exercise, and food quality.concepts/blueprint-protocol.md

Blueprint Protocol

The Blueprint Protocol is bryan johnson’s closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs and biomarkers should have more authority than cravings or cultural defaults.

Design pattern

The protocol has the structure of an autonomous control system:

  1. Sensors: bloodwork, imaging, sleep data, fitness tests, oral/skin/organ metrics, epigenetic clocks, and other biomarkers.
  2. Objective: reduce speed of aging and optimize organ/biomarker states.
  3. Policy: diet, exercise, sleep, supplements, medications, light, heat, oral care, and other interventions.
  4. Feedback: repeat measurements and adjust.
  5. Public ledger: publish routines/results through the web, X/Twitter, and Blueprint content.

Aviation/checklist origin narrative

In a July 28, 2026 autobiographical essay, Johnson traced this control-system style to flight training. He described aviation as a culture that assumes human fallibility and responds with preflight checks, phase-specific procedures, emergency manuals, and active risk management. He says he transferred that logic to food decisions by having “Morning Bryan” set a no-food-after-5 p.m. rule before the lower-willpower evening period, then expanded the system to food type, amount, and timing.

The essay is useful for understanding why Blueprint is presented as automation rather than daily willpower: Johnson links aviation, Kernel, AI, and the “Autonomous Self” directly to Don’t Die. It remains a personal retrospective. It does not establish that the meal cutoff caused his reported sleep, weight, fatigue, or energy changes; it is not a universal meal-timing recommendation or evidence that the system treats depression.

Current protocol stack

The public 2026 protocol emphasizes foundational habits: lower resting heart rate before bed, earlier meals, screens off before bed, consistent sleep, exercise, nutrient-dense food, oral hygiene, skin/hair routines, clean water, and measurement.

Johnson’s May 24, 2026 sleep post adds a tactical version of the same sleep discipline: when expecting to stay up past his 8pm bedtime, he said he took a nap first and argued that “front-loading” sleep is preferable to trying to repay sleep debt afterward because circadian timing still matters. This should be read as Johnson’s personal protocol advice rather than a general medical recommendation.

Johnson’s April 2026 morning routine is an example implementation: 8:30pm bedtime, ~5am wake, oral hygiene, 10,000 lux light, breath work, pre-workout nutrition/supplements, 90 minutes exercise, sauna, red/NIR light, optional shockwave therapy, shower/hair/skincare, and a breakfast of vegetables/legumes/EVOO/berries/nuts/seeds.

On June 19, 2026, a high-engagement routine post compressed that posture into a seven-day checklist: stop food four hours before sleep, screens off 60 minutes before bed, read for 10 minutes before sleep, get light in the eyes on waking, and exercise daily. It is useful as a current, low-tech summary of Johnson’s recurring sleep/wake advice; it should still be presented as his habit framing rather than personalized medical guidance.

On July 23, Johnson supplied a compact meal-timing feedback example: he reported a sleep heart rate of 42 bpm when he finished eating at noon versus 44 bpm when he finished at 2 p.m. The value for understanding Blueprint is the input/output framing—small behavioral changes become measured protocol variables—not the two readings as universal targets or proof that meal timing alone caused the difference.

Iteration and reversals

The protocol is not static. Johnson’s public posts include stopping or pausing interventions when measurements disappoint. A 2025 @bryan_johnson post says he paused metformin after five years because it appeared to build energy capacity while limiting his ability to use much of it.

Prescription-therapeutics expansion

On June 9, 2026, Johnson announced a prescription medication platform under the Blueprint/Don’t Die umbrella, naming Tadalafil/Cialis, Metformin, Oral Minoxidil, Tretinoin, Estradiol, and Acarbose as prescriptions he personally uses and says are dispensed through licensed doctors and pharmacies. This is a meaningful product expansion from routines, supplements, foods, tests, and certified products into clinician-mediated prescription access.

On June 12, he gave one concrete example: daily 5 mg Tadalafil/Cialis, which he framed as blood-flow/longevity support and not just sexual-health treatment. The public claim cites observational associations with lower mortality and cardiovascular/neurological outcomes, but Johnson’s own post caveats that association is not causation and that the information is not medical advice. The dashboard should preserve that distinction: useful evidence of where Blueprint is moving, not a treatment recommendation.

On June 22, Johnson announced a major expansion of the same prescription layer, now branded Immortals Rx, under the headline “microdose GLP-1s,” “peptides,” and “NAD+.” Newly listed items included semaglutide/Wegovy, tirzepatide/Zepbound, SGLT2 inhibitors Jardiance and Brenzavvy, additional sex/arousal/skin/hair peptide complexes, glutathione, and NAD+, alongside the existing tadalafil/metformin/minoxidil/tretinoin/acarbose stack. This is the strongest public signal so far that the Rx business is widening from a short list of Johnson’s own drugs into GLP-1, peptide, and NAD+ catalogs. It should be presented as Immortals/Blueprint commercial positioning; off-label longevity efficacy and safety are not established by the announcement.

On July 22, Johnson made the GLP-1 catalog more specific, saying Immortals Rx now lists six options: Zepbound, Wegovy injections, Wegovy tablets, Foundayo tablets, compounded tirzepatide, and compounded semaglutide. He tied the list to weight loss, “food noise,” and possible longevity relevance after an Australia time-zone shift. This is a concrete commercial update, but the post names no studies and does not independently establish formulation status, availability, prescribing criteria, compounded-treatment safety, or efficacy for longevity.

On August 3, Johnson extended the prescription narrative into cancer research by quote-posting a summary claiming that sildenafil plus statins may interfere with tumor-cell cholesterol use. He cited lower colorectal-cancer mortality and metastasis figures and proposed that the mechanism could apply to tadalafil, while explicitly saying the study was preclinical and human evidence observational. This does not announce a new product or protocol and does not establish that sildenafil, tadalafil, or statins prevent metastasis. It remains a low-confidence interpretation linked to an existing commercial prescription line, not treatment guidance.

Jet lag and routine snapshots

The June 2026 batch also included self-reported jet-lag recovery timelines and a caffeine + melatonin recovery protocol Johnson said he was testing, plus a breakfast snapshot centered on vegetables, legumes, mushrooms, herbs, seeds, and olive oil. These are examples of the measurement loop in public: an intervention or routine is narrated, tied to biomarkers or recovery, then folded back into the protocol story.

On July 22, Johnson posted another personal routine snapshot: asleep at 8 p.m., awake at 4:30 a.m., then breathwork, oral care, light and red-light exposure, protein/collagen/EVOO/berries, IHHT, work, stool/saliva/blood/urine testing, exercise, a 200°F dry sauna, and a later plant-led meal. It documents his current stack but is not evidence that the combined routine improves longevity or a template readers should follow.

On June 18, Johnson posted the outcome half of that jet-lag test after returning from Australia: 300 mg caffeine in the morning plus 3 mg melatonin before bed, which he said accelerated body-clock resynchronization and was observable “live” via blood glucose. This is useful as protocol logging and follow-up, but still N=1 self-report rather than dosing guidance or proof that the intervention caused recovery.

Microbiome product — Akkermansia + butyrate

The same June 18 source also added a commercial protocol/product signal: Blueprint launched a microbiome supplement pairing Akkermansia muciniphila with butyrate triglycerides. Johnson framed Akkermansia around age-related decline, gut-barrier integrity, glucose regulation, insulin sensitivity, and Amuc_1100/TLR2 signaling, while framing butyrate triglycerides as direct epithelial support. The dashboard should separate those mechanism claims from product-specific evidence; the launch is notable, but not independent validation of gut or metabolic benefit.

Skin / UV protection

On June 19, 2026, Johnson posted a skin-aging self-measurement from his Australia trip: he claimed one week of Australian sun increased his skin aging by about 5% via UV damage/spots despite umbrella and peak-UV protection, then added in a reply that he has reversed his skin age by roughly 9 years since starting the project. He cited a 1,472-person comparison where Australian women showed skin-aging signs 10–20 years earlier than US women, but did not provide a full citation in-tweet. For the dashboard, this is best treated as another Blueprint readout example — skin/UV risk quantified as a metric — not independent validation of the 5% or 9-year figures and not individualized skincare advice.

Sauna heat-dose / HSP27 testing

On June 16, 2026, Johnson posted a three-session dry-sauna experiment using an ingestible temperature capsule with 30-second core-temperature readings, repeated blood draws, and specialty biomarkers. His stated question was whether sauna benefit depends on elapsed time or on body-temperature dose. Johnson claims HSP27 increased only in sessions where his core temperature stayed above 102.2°F / 39°C for roughly 15 minutes, while a shorter time above that threshold did not produce the same response.

This is useful for the dashboard because it shows Blueprint’s protocol-iteration style: define a measurable mechanism, track delivered dose inside the body, compare response, then revise the practical rule. It should not be rendered as a public sauna prescription. Extreme heat exposure can be risky, and Johnson’s thread remains N=1 biomarker evidence rather than independent proof of clinical longevity benefit.

A June 17 follow-up added a heart-rate trace from the same 56-minute 200°F / 93°C session, with Johnson reporting a 128–133 bpm peak and a spike when changing ice on his face, neck, and groin. The extra datapoint is dashboard-useful mainly because it shows how Blueprint experiments now publish physiological traces alongside biomarker claims; it does not change the N=1 status or safety caveats.

On July 23, Johnson broadened that experiment into public protocol guidance: 4–7 dry-sauna sessions per week; example thresholds of 11 minutes at 176°F / 80°C and 20 minutes at 195°F / 90.5°C; a personal path to 102.2°F / 39°C core temperature; and cautions or claims spanning acclimation, hydration/electrolytes, fertility, cold plunging, recovery, microplastics, air quality, sauna materials, clothing, and heat tolerance. The expansion is editorially important because it crosses from documenting one measured experiment into telling an audience what to do. Every item therefore remains explicitly attributed to Johnson; the post does not independently validate the dry-versus-wet/infrared distinction, the benefit thresholds, the fertility or microplastics claims, or a reader-safe universal protocol.

N-of-1 methodology essay (June 2026)

The same daily batch included Johnson’s most formal public defense of Blueprint’s method to date, prompted by a Nature feature. With the Blueprint & Immortals Medical and Science Team, he argued that RCTs remain the gold standard for population average effects and safety, but are structurally limited for tuning individualized intervention combinations over time. For the public KB, this is best treated as a methodology update: it clarifies why Blueprint keeps emphasizing dense personal measurement, while also making the evidence boundary explicit because the essay’s examples are still observations needing validation.

Critical context: changes are hard to interpret because dozens of variables move at once. In conventional evidence hierarchy, this is hypothesis-generating self-experimentation, not proof of general efficacy.

Disease-resolution and eye-health agenda

On July 20, 2026, Johnson said an unspecified incurable-disease diagnosis had shifted his project from “longevity staples” toward disease resolution and frontier biotech. In a separate eye-health thread that day, he distinguished general diet and supplement discussion from what he wants to see: robust measurement, diagnosis of dysfunction, and protocols intended to correct it. Together the posts suggest a change in emphasis—from broad longevity routines toward disease- and organ-specific engineering—but they do not identify the disease, measurement set, dysfunction, intervention, or outcome. The dashboard records a strategic agenda, not a demonstrated protocol, cure, or reader medical guidance.

On July 21, the eye-health agenda gained a concrete measurement but still no public protocol: Johnson reported collecting tears with paper strips for a $1,800 specialty-lab panel across 15 inflammatory, tissue-degradation, and regenerative-signaling biomarkers. He said the readings would establish the ocular-surface environment and track progress, with an eye protocol forthcoming. No result, diagnosis, intervention, reference range, clinical-utility evidence, or outcome was published, so the dashboard records an N=1 measurement plan rather than eye-health guidance.

On August 18, the agenda landed a diagnosis and a disclosed intervention stack. After visiting an eye doctor for a stye, Johnson said infrared meibography and Schirmer testing showed advanced meibomian-gland dysfunction with meaningful gland dropout plus concurrent aqueous deficiency. He published a four-therapy in-office stack—intense pulsed light, radiofrequency, intraductal probing (the Maskin protocol), and 630nm low-level red light—alongside home compresses, preservative-free and lipid-replacement drops, and tear-stimulation devices, and reported a self-measured 30% improvement in gland function on imaging. He also named systemic drivers that sit inside his own longevity protocol: a topical anti-androgen used for hair growth, low insulin/IGF-1 signaling, and a prior subclinical thyroid flare. The post itself concedes the probing science is unsettled and that four simultaneous therapies cannot be attributed individually. The dashboard records an attributed N=1 diagnosis-and-intervention account—not a validated eye-care protocol, evidence the therapies work in general, or medical advice.

Immortals disease infrastructure and female-health baseline

On July 24, Johnson described Immortals’ disease-resolution pivot as a company buildout. Alongside the existing nutrition, prescription, hormone, peptide, biomarker, and concierge layers, he named induced pluripotent stem cells, organoids, deep cellular characterization, and personalized therapy development as new directions intended to help individuals investigate and resolve their own health issues. This extends Blueprint’s measure–intervene–retest loop toward personalized biotech R&D, but the post does not establish an operational clinical platform, diagnostic accuracy, treatment safety, or any cure or outcome.

On July 25, Johnson published a more operational version of Kate Tolo’s baseline: 100 days before interventions, 14 million claimed menstrual-cycle data points, 100+ tasks a day, 50+ devices, and a 12-person medical team. The schedule combines repeated biological samples, hormone and metabolic measures, functional and sensory tests, imaging, wearables, microbiome work, exercise, sleep, mood, and routine care. Its dashboard value is visibility into protocol operations and burden; it remains a single N=1 program with no published results, validated general female-health protocol, or reader guidance.

On August 4, Johnson compared the build process directly: he said his own longevity infrastructure took five years to assemble, including the doctors, protocols, measurements, and mistakes, while his team built Tolo’s protocol in 90 days and made it “better.” The notable signal is operational rather than clinical—Blueprint is being presented as infrastructure a team can reproduce and improve, not only as Johnson’s personal N=1 routine. The source does not define “better,” publish comparative measurements, or report outcomes, so it is not evidence that Tolo’s protocol is clinically superior, generalizable, or appropriate for readers.

August measurement-scale and research-watch updates

On August 12, Johnson reported a 47-tube, 250 mL blood draw for single-cell sequencing of circulating immune cells and a broad panel spanning inflammation, oxidative stress, vascular health, metabolic and lipid regulation, glucose regulation, and brain-related signals. On August 13, he promoted a Baseten event organized around biological-age evaluations for brain, skin, strength, balance, reaction speed, and mobility. Together the posts show Blueprint’s continued emphasis on molecular depth plus functional breadth, but neither publishes results, test-validity evidence, a diagnosis, or a protocol change readers should copy.

Johnson also summarized an unnamed mouse study in which an intranasal gene therapy reportedly restored age-reduced downstream brain-fluid flow. This is relevant to his longevity-research narrative, not evidence that Blueprint uses the intervention or that a human therapy is available. The post supplies no paper, human data, translational safety evidence, or clinical outcome.

Automation analogy

Johnson explicitly connects Blueprint to automation: in a 2024 X post he wrote that the era is defined by automation in software engineering, self-driving, and health/wellness, and that Blueprint is automation toward peak health and age escape velocity.

This makes Blueprint relevant to the wiki’s AI-agent themes: it is essentially an agentic/self-driving loop over the body, with measurements as context, protocols as tools, and biological age as reward signal.

Evidence tiers

TierExamplesConfidence
Foundationalsleep, exercise, nutrient-dense diet, oral care, reduced alcohol/junk foodHigh for general health, not necessarily immortality
Measurementbloodwork, DEXA, wearable sleep/fitness, BP, glucoseMedium/high for monitoring; depends on interpretation
Supplementsomega-3, creatine, vitamin D, NR/NMN, large stacksMixed; stack interactions not proven
Experimentalplasma exchange, gene therapy, peptides, stem cells, extensive off-label therapiesLow/contested for longevity claims